Table 5.
Endpoints after 24 and 48 weeks of treatment
| Outcomes | Median (IQR) |
P
24/48 weeks |
||
|---|---|---|---|---|
| Baseline | Week 24 | Week 48 | ||
| CD4+ cell count | 245 (129–400) | 311 (239–522) | 378 (252–559) | <0.001* |
| HIV-1 RNA viral load | 22,600 (3590–75,797) | <50 (<50–82) | <50 (<50–85) | <0.001* |
| Cholesterol (mg/dL) | 167 (364–195) | 174 (156–214) | 185 (150–214) | 0.004/<0.001 |
| Triglycerides (mg/dL) | 186 (135–260) | 197 (148–271) | 220 (162–305) | 0.465/0.076 |
| Creatinine (mg/dL) | 0.86 (0.70–1.0) | 0.9 (0.8–1.07) | 0.9 (0.8–1.05) | <0.001* |
* At both 24 and 48 weeks